GDTC CytoMed Return on Gross Profit

Corporate emblem and logo of CytoMed Therapeutics Limited (GDTC)

The gross margin of the business demonstrates CytoMed Therapeutics (GDTC) independence from macroeconomic trends, as demand for oncology therapy is non-cyclical. The parameter value is -286.20, which captures the company's operational status. Growth potential is based on unique donor T-cell vaccines that guarantee pricing power. Meanwhile, operations rely on strict medical regulations for biomaterial disposal and back-office environmental standards.

Gross Margin: CytoMed Therapeutics (GDTC) for 02/21/2024 - 11/20/2026

Comprehensive metric breakdowns and analytics for w2.cytomed.sg (GDTC)

- stock value and consensus price forecast:
Fundamental valuation:CytoMed Therapeutics (GDTC)
Manufactured products of CytoMed Therapeutics

To assess the credit quality of CytoMed Therapeutics (GDTC), the analyst examines the gross profit margin, which measures the portion of revenue remaining after deducting direct production costs, allowing one-off anomalies to be isolated from the systemic trend. The ability of CytoMed Therapeutics to implement affordable, universal T-cells reduces the cost of therapy, which should be reflected in the steady growth of this indicator and confirm the company's market advantage.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|CRIS - Return on Gross Profit|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit